COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 255.1 | 3 | 0107-0434 | 108.10 | 433.85 | 387 | 73.84 | 0.892 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 233.4 | 3 | 0108-0437 | 59.84 | 437.40 | 376 | 72.77 | 0.892 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 549.1 | 3 | 0109-0439 | 611.79 | 439.72 | 327 | 67.26 | 0.908 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 611.0 | 3 | 0110-0452 | 856.28 | 453.15 | 186 | 66.77 | 0.524 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 436.6 | 3 | 0111-0462 | 894.04 | 461.91 | 377 | 72.43 | 0.903 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 262.5 | 3 | 0112-0469 | 598.73 | 470.62 | 823 | 111.54 | 0.831 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 278.1 | 3 | 0113-0466 | 199.40 | 465.88 | 395 | 76.43 | 0.850 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 398.5 | 3 | 0114-0463 | 864.99 | 464.80 | 169 | 61.11 | 0.569 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 257.1 | 3 | 0115-0468 | 18.62 | 468.60 | 375 | 72.43 | 0.898 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 234.4 | 3 | 0116-0477 | 537.51 | 477.00 | 395 | 73.84 | 0.910 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 224.8 | 3 | 0117-0480 | 53.51 | 480.49 | 349 | 71.60 | 0.856 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 257.7 | 3 | 0118-0489 | 512.63 | 489.10 | 419 | 78.33 | 0.858 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 246.7 | 3 | 0119-0487 | 713.79 | 487.75 | 393 | 75.01 | 0.878 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 291.0 | 3 | 0120-0488 | 757.30 | 487.96 | 396 | 76.43 | 0.852 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 259.8 | 3 | 0121-0496 | 472.71 | 496.72 | 389 | 73.60 | 0.902 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 241.1 | 3 | 0122-0498 | 409.66 | 497.78 | 366 | 71.60 | 0.897 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 226.2 | 3 | 0123-0503 | 35.08 | 503.00 | 328 | 68.77 | 0.872 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 269.3 | 3 | 0124-0506 | 169.29 | 506.84 | 401 | 77.60 | 0.837 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 608.0 | 3 | 0125-0503 | 870.94 | 502.71 | 369 | 74.43 | 0.837 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 256.8 | 3 | 0126-0513 | 109.46 | 513.19 | 361 | 72.43 | 0.865 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 279.0 | 3 | 0127-0525 | 449.52 | 527.03 | 799 | 124.81 | 0.645 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 283.6 | 3 | 0128-0515 | 252.53 | 515.56 | 362 | 73.84 | 0.834 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 255.0 | 3 | 0129-0517 | 190.70 | 517.05 | 390 | 76.33 | 0.841 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 367.4 | 3 | 0130-0517 | 776.83 | 517.42 | 340 | 68.43 | 0.913 |
COLO 858 | Vemurafenib | 0.316 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 360.6 | 3 | 0131-0515 | 808.51 | 515.00 | 361 | 70.77 | 0.906 |